Culture technology have permitted the generation of an artificial skin using human neonatal stem cells. A major advantage of this model is that epithelial-mesenchymal interactions are maintained. We have studied some morphological aspects concerning tissue organisation and cell differentiation using immunohistochemistry and electron microscopy. The epidermal equivalent was composed by a stratif...

Bioengineered organs raised in vitro are candidate substitutes for natural organs in biological, pharmacological and clinical applications. We have studied cell kinetics in a human skin equivalent (HSE) using a combined immunohistochemical and flow cytometric approach. Morphological analysis has shown that, relative to unstimulated natural skin, cell proliferation mainly occurs in the basal lay...

Hemosol has been one of the pioneering leaders working since 1985 in an effort to bring to market a human hemoglobin based oxygen therapeutic which would serve several important clinical needs. Hemosol welcomes the publication of this most current Guidance document as a timely response to many major developments in this field in the past near-decade. Below Hemosol first offers some general comm...

The repair or replacement of damaged skins is still an important, challenging public health problem. Immune acceptance and long-term survival of skin grafts represent the major problem to overcome in grafting given that in most situations autografts cannot be used. The emergence of artificial skin substitutes provides alternative treatment with the capacity to reduce the dependency on the incre...

In vitro T-cell based interferony (IFNy) release assays (IGRAs), the QuantiFERON-TB Gold In-Tube test (QFN-GIT) (Cellestis Limited, Carnegie, Victoria, Australia) and the T-SPOT. TB test (T-Spot) (Oxford Immunotec Limited, Abingdon, United Kingdom), are marketed as a substitute for the tuberculin skin test (TST). The specificity of these immunoassays has been optimised by using Mycobacterium tu...